Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9012916 | 0.84 | MEN1 (0.49) | OPRK1MEN1KMT2AL3MBTL1 | |
| SCHEMBL6541359 | 0.84 | TAS2R14 (0.48) | TAS2R14ESR1FNTAFNTBOPRD1 | |
| SCHEMBL6540352 | 0.79 | MEN1 (0.42) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL6540822 | 0.77 | TAS2R14 (0.57) | TAS2R14ESR1FNTAFNTBMEN1 | |
| SCHEMBL7420161 | 0.75 | OPRD1 (0.56) | TAS2R14OPRD1OPRK1OPRM1KMT2A | |
| SCHEMBL7420165 | 0.75 | OPRD1 (0.56) | TAS2R14OPRD1OPRK1OPRM1KMT2A | |
| SCHEMBL6541038 | 0.72 | CNR1 (0.47) | OPRD1OPRK1MEN1KMT2A | |
| SCHEMBL6539625 | 0.71 | BACE1 (0.44) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6798502 | 0.71 | CA12 (0.55) | TAS2R14ESR1L3MBTL1 | |
| SCHEMBL1642165 | 0.70 | KMT2A (0.51) | MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | TAS2R14 3056/4885ESR1 2525/4885FNTA 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.